A phase II study of everolimus in combination with imatinib for previously treated advanced renal carcinoma

Christopher Ryan, Jacqueline Vuky, Joseph S. Chan, Zunqiu Chen, Tomasz (Tom) Beer, Deirdre Nauman

    Research output: Contribution to journalArticle

    8 Citations (Scopus)

    Abstract

    Purpose: This phase II study evaluated the activity of combined treatment with the mTOR inhibitor everolimus and the PDGFR inhibitor imatinib in patients with previously-treated, advanced renal carcinoma. The primary endpoint was estimation of the 3-month progression-free rate. Patients and methods: Eligible patients had metastatic or unresectable clear cell renal carcinoma, at least one prior systemic therapy, no prior mTOR inhibitor therapy, performance status 0-2, and measurable disease. Treatment consisted of everolimus 2.5 mg p.o. daily and imatinib 600 mg p.o. daily. The primary endpoint was the 3-month progression-free rate. Results: The study was closed after the first 19 patients because of an insufficient number of patients who were progression-free at 3 months. The 3-month progression-free rate was 49% (95% C.I. 23%, 72%) and the median progression-free survival was 2.9 months (95% C.I. 1.9, 6.2). Toxicities with an incidence of >50% included nausea, elevated serum creatinine, edema, anemia, hypocalcemia, fatigue, diarrhea, vomiting, and dyspnea, and leukopenia. Conclusion: The combination of everolimus with imatinib in previously treated patients with advanced renal carcinoma did not result in a sufficient 3-month progression-free rate to warrant further investigation of this combination.

    Original languageEnglish (US)
    Pages (from-to)374-379
    Number of pages6
    JournalInvestigational New Drugs
    Volume29
    Issue number2
    DOIs
    StatePublished - Apr 2011

    Fingerprint

    Carcinoma
    Kidney
    Hypocalcemia
    Leukopenia
    Therapeutics
    Renal Cell Carcinoma
    Dyspnea
    Nausea
    Disease-Free Survival
    Vomiting
    Fatigue
    Everolimus
    Imatinib Mesylate
    Anemia
    Diarrhea
    Edema
    Creatinine
    Incidence
    Serum

    Keywords

    • Everolimus
    • Imatinib
    • Phase II clinical trial
    • Renal cell carcinoma

    ASJC Scopus subject areas

    • Pharmacology
    • Pharmacology (medical)
    • Oncology

    Cite this

    A phase II study of everolimus in combination with imatinib for previously treated advanced renal carcinoma. / Ryan, Christopher; Vuky, Jacqueline; Chan, Joseph S.; Chen, Zunqiu; Beer, Tomasz (Tom); Nauman, Deirdre.

    In: Investigational New Drugs, Vol. 29, No. 2, 04.2011, p. 374-379.

    Research output: Contribution to journalArticle

    @article{88b2d04915b64addaee961a5782525cf,
    title = "A phase II study of everolimus in combination with imatinib for previously treated advanced renal carcinoma",
    abstract = "Purpose: This phase II study evaluated the activity of combined treatment with the mTOR inhibitor everolimus and the PDGFR inhibitor imatinib in patients with previously-treated, advanced renal carcinoma. The primary endpoint was estimation of the 3-month progression-free rate. Patients and methods: Eligible patients had metastatic or unresectable clear cell renal carcinoma, at least one prior systemic therapy, no prior mTOR inhibitor therapy, performance status 0-2, and measurable disease. Treatment consisted of everolimus 2.5 mg p.o. daily and imatinib 600 mg p.o. daily. The primary endpoint was the 3-month progression-free rate. Results: The study was closed after the first 19 patients because of an insufficient number of patients who were progression-free at 3 months. The 3-month progression-free rate was 49{\%} (95{\%} C.I. 23{\%}, 72{\%}) and the median progression-free survival was 2.9 months (95{\%} C.I. 1.9, 6.2). Toxicities with an incidence of >50{\%} included nausea, elevated serum creatinine, edema, anemia, hypocalcemia, fatigue, diarrhea, vomiting, and dyspnea, and leukopenia. Conclusion: The combination of everolimus with imatinib in previously treated patients with advanced renal carcinoma did not result in a sufficient 3-month progression-free rate to warrant further investigation of this combination.",
    keywords = "Everolimus, Imatinib, Phase II clinical trial, Renal cell carcinoma",
    author = "Christopher Ryan and Jacqueline Vuky and Chan, {Joseph S.} and Zunqiu Chen and Beer, {Tomasz (Tom)} and Deirdre Nauman",
    year = "2011",
    month = "4",
    doi = "10.1007/s10637-009-9365-y",
    language = "English (US)",
    volume = "29",
    pages = "374--379",
    journal = "Investigational New Drugs",
    issn = "0167-6997",
    publisher = "Kluwer Academic Publishers",
    number = "2",

    }

    TY - JOUR

    T1 - A phase II study of everolimus in combination with imatinib for previously treated advanced renal carcinoma

    AU - Ryan, Christopher

    AU - Vuky, Jacqueline

    AU - Chan, Joseph S.

    AU - Chen, Zunqiu

    AU - Beer, Tomasz (Tom)

    AU - Nauman, Deirdre

    PY - 2011/4

    Y1 - 2011/4

    N2 - Purpose: This phase II study evaluated the activity of combined treatment with the mTOR inhibitor everolimus and the PDGFR inhibitor imatinib in patients with previously-treated, advanced renal carcinoma. The primary endpoint was estimation of the 3-month progression-free rate. Patients and methods: Eligible patients had metastatic or unresectable clear cell renal carcinoma, at least one prior systemic therapy, no prior mTOR inhibitor therapy, performance status 0-2, and measurable disease. Treatment consisted of everolimus 2.5 mg p.o. daily and imatinib 600 mg p.o. daily. The primary endpoint was the 3-month progression-free rate. Results: The study was closed after the first 19 patients because of an insufficient number of patients who were progression-free at 3 months. The 3-month progression-free rate was 49% (95% C.I. 23%, 72%) and the median progression-free survival was 2.9 months (95% C.I. 1.9, 6.2). Toxicities with an incidence of >50% included nausea, elevated serum creatinine, edema, anemia, hypocalcemia, fatigue, diarrhea, vomiting, and dyspnea, and leukopenia. Conclusion: The combination of everolimus with imatinib in previously treated patients with advanced renal carcinoma did not result in a sufficient 3-month progression-free rate to warrant further investigation of this combination.

    AB - Purpose: This phase II study evaluated the activity of combined treatment with the mTOR inhibitor everolimus and the PDGFR inhibitor imatinib in patients with previously-treated, advanced renal carcinoma. The primary endpoint was estimation of the 3-month progression-free rate. Patients and methods: Eligible patients had metastatic or unresectable clear cell renal carcinoma, at least one prior systemic therapy, no prior mTOR inhibitor therapy, performance status 0-2, and measurable disease. Treatment consisted of everolimus 2.5 mg p.o. daily and imatinib 600 mg p.o. daily. The primary endpoint was the 3-month progression-free rate. Results: The study was closed after the first 19 patients because of an insufficient number of patients who were progression-free at 3 months. The 3-month progression-free rate was 49% (95% C.I. 23%, 72%) and the median progression-free survival was 2.9 months (95% C.I. 1.9, 6.2). Toxicities with an incidence of >50% included nausea, elevated serum creatinine, edema, anemia, hypocalcemia, fatigue, diarrhea, vomiting, and dyspnea, and leukopenia. Conclusion: The combination of everolimus with imatinib in previously treated patients with advanced renal carcinoma did not result in a sufficient 3-month progression-free rate to warrant further investigation of this combination.

    KW - Everolimus

    KW - Imatinib

    KW - Phase II clinical trial

    KW - Renal cell carcinoma

    UR - http://www.scopus.com/inward/record.url?scp=79957552225&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=79957552225&partnerID=8YFLogxK

    U2 - 10.1007/s10637-009-9365-y

    DO - 10.1007/s10637-009-9365-y

    M3 - Article

    C2 - 20012337

    AN - SCOPUS:79957552225

    VL - 29

    SP - 374

    EP - 379

    JO - Investigational New Drugs

    JF - Investigational New Drugs

    SN - 0167-6997

    IS - 2

    ER -